Linagliptin improves glycemic control by inhibiting dipeptidase -4 (DPP-4).
*The following content is generated by AI and is for reference only.
Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in diabetes management. It features a unique non-hydrolyzable xanthine scaffold. Molecular Formula: C25H31N7O2. CAS No.: 850519-68-1.
Application
- Pharmaceutical manufacturing of oral antidiabetic tablets.
- R&D for combination therapies with metformin or insulin.
- Regulatory compliance testing for active pharmaceutical ingredients.
Precautions
Store below 25°C in dry conditions. Avoid inhalation of dust; use appropriate PPE during handling. Contraindicated in patients with severe renal impairment requiring dose adjustment or hypersensitivity to the compound.